Eli Lilly price target lowered to $973 from $995 at Guggenheim
Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Hims & Hers Health down 3% after BoA says Q4 revenue could be a miss
Hims & Hers Health is down ~3% in Friday morning trading after an analyst note from BofA Securities stated that the company's ...
Investor's Business Daily on MSN15h
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...
Novo Nordisk price target raised to DKK 798 from DKK 795 at Guggenheim
Guggenheim raised the firm’s price target on Novo Nordisk (NVO) to DKK 798 from DKK 795 and keeps a Buy rating on the shares. The firm is ...
US open: Stocks higher going into MLK Day long weekend
On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...
Morningstar17h
Global Sustainable Fund Flows: Q3 2024 in Review
In the third quarter of 2024, sustainable open-end and exchange-traded funds witnessed a surge in net new money, drawing in an estimated USD 10.4 billion. This represents a significant increase ...